Prevention of nevirapine-associated rash [6]

Lancet

Volumn 357, Issue 9253, 2001, Pages 392-393

  Colebunders, R ^a   Schrooten, W ^a   Desmet, P ^a   Roo, A De ^a   Dreezen, C ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LORATADINE; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIBIDO; LONG TERM CARE; PENIS ERECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; DRUG ERUPTION; NOTE; CHEMICALLY INDUCED DISORDER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; SEXUAL DYSFUNCTION;

ANTI-HIV AGENTS; DRUG ERUPTIONS; HUMANS; NEVIRAPINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV PROTEASE INHIBITORS; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 0035798941     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)71525-7     Document Type: Letter

References (3)

1. A Carr DA Cooper Adverse effects of antiretroviral therapy Lancet 356 2000 1423 1430
2. R Colebunders E Smets K Verdonck C Dreezen Sexual dysfunction with protease inhibitors Lancet 353 1999 1802
3. Colebunders R, Dreezen C, Pernetun T, de Mey I, Verdonck I, Schrooten W. Sexual dysfunction associated with protease inhibitory treatments. Proceedings of the 13th International AIDS Conference, July, 2000, Durban, South Africa (abstr WePeB4263).